Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormonereceptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study

MLA

Jimenez, Mm, et al. Overall Survival (OS) of Palbociclib (P) plus Endocrine Therapy (ET) versus Capecitabine (CAP) in Hormonereceptor+/HER2-Metastatic Breast Cancer (MBC) That Progressed on Aromatase Inhibitors (AIs): Final Results of the PEARL Study. Jan. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....0fee28c3aef451538129fd7d7918a35a&authtype=sso&custid=ns315887.

APA

Jimenez, M., Zielinski, C., Ruiz-Borrego, M., Carrasco, E., Ciruelos, E., Munoz, M., Bermejo, B., Margeli, M., Csoszi, T., Anton, A., Turner, N., Casas, M., Morales, S., Alba, E., Calvo, L., De la Haba, J., Ramos, M., Corsaro, M., Kahan, Z., & Gil-Gil, M. (2021). Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormonereceptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study.

Chicago

Jimenez, Mm, C Zielinski, M Ruiz-Borrego, E Carrasco, Em Ciruelos, M Munoz, B Bermejo, et al. 2021. “Overall Survival (OS) of Palbociclib (P) plus Endocrine Therapy (ET) versus Capecitabine (CAP) in Hormonereceptor+/HER2-Metastatic Breast Cancer (MBC) That Progressed on Aromatase Inhibitors (AIs): Final Results of the PEARL Study,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....0fee28c3aef451538129fd7d7918a35a&authtype=sso&custid=ns315887.